Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by PORTER, D. R.
Right arrow Articles by THOMSON, E. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by PORTER, D. R.
Right arrow Articles by THOMSON, E. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1996 British Society for Rheumatology

other

IS RHEUMATOID ARTHRITIS BECOMING A MILDER DISEASE? OR ARE WE STARTING SECOND-LINE THERAPY IN PATIENTS WITH MILDER DISEASE?

D. R. PORTER*, H. A. CAPELL, I. MCINNES, R. MUNRO, R. MADHOK, J. A. HUNTER* and E. A. THOMSON

Royal Infirmary General Hospital Glasgow
*Gartnavel General Hospital Glasgow

The aim of the study was to see whether rheumatoid arthritis (RA) is becoming a milder disease. Information on the initial disease activity and patient function (modified Health Assessment Questionnaire-HAQ) was collected in all RA patients enrolled into studies of sulphasalazine since 1980 in two Glasgow teaching hospitals. Patients (352) were enrolled in trials in the decade 1980–1989, and were compared to 374 patients enrolled in 1990–1994. Patients recruited in the 1980s were significantly younger, but had a similar disease duration to the 1990s patients. The 1980s patients had more active disease as measured by erythrocyte sedimentation rate (61 vs44, P < 0.0001) and C-reactive protein (40 vs 26, P &.t; 0.0001), and significantly worse function (HAQ 2.3 vs 1.9, P < 0.001). The response to sulphasalazine was very similar in the two cohorts, in terms of the percentage of patients remaining on therapy for 6 months, and the percentage improvement in measures of disease activity. Patients with milder disease were enrolled into the more recent trials of sulphasalazine. This may be because RA is becoming a milder disease, but other possible explanations are discussed

KEY WORDS: Rheumatoid arthritis, Disease severity, Patient function


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann Rheum DisHome page
N Maiden, H A Capell, R Madhok, R Hampson, and E A Thomson
Does social disadvantage contribute to the excess mortality in rheumatoid arthritis patients?
Ann Rheum Dis, September 1, 1999; 58(9): 525 - 529.
[Abstract] [Full Text]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.